Showing 5611-5620 of 9511 results for "".
- BTL to Launch Small Emsculpt Applicator for Arms, Thighs, Calveshttps://practicaldermatology.com/news/btl-to-launch-small-emsculpt-applicator-for-arms-thighs-calves/2459955/BTL is rolling out a small Emsculpt applicator to treat arms, thighs and calves at the annual meeting of the American Society for Laser Medicine and Surgery in Denver. Until now, there were only protocols for the abdominals and buttocks. In addition to launching the small appl
- Now Available: neuLASH Professional and neuBROW Professionalhttps://practicaldermatology.com/news/now-available-neulash-professional-and-neubrow-professional/2459956/New from Skin Research Professional and Olive and Delmar, neuLASH PROFESSIONAL™ and neuBROW PROFESSIONAL™ are available in all new, next-generation, professional-strength formulations. neuLASH PROFESSIONAL™ is a peptide serum promoting longer-looking lashes and neuBROW PROFESS
- Allergan Acquires Envy Medical, Inc.https://practicaldermatology.com/news/allergan-acquires-envy-medical-inc/2459957/Allergan now owns Envy Medical, Inc. The acquisition adds Envy's Dermalinfusion, a non-surgical, non-invasive skin resurfacing system for the face and body, to Allergan's portfolio. Offered in physician's offices, medical spas and l
- Biofrontera Acquires Cutanea Life Scienceshttps://practicaldermatology.com/news/biofrontera-acquires-cutanea-life-sciences/2459959/Biofrontera Inc., USA entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan as the seller. Maruho holds approximately 20 percent of Biofrontera AG. Cutanea is a US-based phar
- Biofrontera Reports Positive Phase 3 Results with Ameluz for PDT of AKs on Extremities and Trunk/Neckhttps://practicaldermatology.com/news/biofrontera-reports-positive-phase-3-results-with-ameluz-for-pdt-of-aks-on-extremities-and-trunkneck/2459961/Results for the primary endpoint of Biofrontera AG's Phase 3 clinical trial evaluating the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz and the BF-RhodoLED lamp for the treatment of actinic keratoses (AK) on the extremities as well as the trunk and neck are posti
- AAD Announces 2019 Election Resultshttps://practicaldermatology.com/news/aad-announces-2019-election-results/2459967/The votes have been counted in the 2019 AAD Election, and the following candidates will take office at the conclusion of the 2020 Annual Meeting in Denver, Colorado on March 24, 2020.
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of D
- Constellation Alpha Capital Corp. Signs Letter of Intent to Acquire DermTech, Inc.https://practicaldermatology.com/news/constellation-alpha-capital-corp-signs-letter-of-intent-to-acquire-dermtech-inc/2459970/Constellation Alpha Capital Corp., a special purpose acquisition company, has executed a non-binding Letter of Intent to merge with DermTech, Inc., a molecular genomics company with an initial focus on skin cancer. DermTech markets and develops products that facilitate the early detection of skin
- Study: Port Wine Stain Laser Treatment Is Safe and Effective in Infants Without Anesthesiahttps://practicaldermatology.com/news/study-port-wine-stain-laser-treatment-is-safe-and-effective-in-infants-without-anesthesia/2459974/Recent concerns about the repetitive use of general anesthesia in children younger than 3 have placed greater importance on the controversy surrounding the timing of port-wine stain laser treatment, but a new
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription